ProQR Therapeutics N.V. (PRQR) Balance Sheet

The consistent decline in total assets suggests that the company is consuming its capital base to fund R&D without replenishing it through commercial success. This trajectory implies that the firm is becoming increasingly reliant on external financing or milestone payments to maintain its operational footprint.

While the current ratio of 2.48 remains technically adequate, the rapid depletion of cash reserves relative to the company's high operating burn rate warrants close monitoring. Investors should consider that this liquidity profile leaves little room for error in clinical trial execution or unexpected delays in milestone achievement.

The company's debt appears to be a tactical tool rather than a structural necessity, given the lack of commercial cash flow to service interest obligations. The volatility in the D/E ratio reflects the company's ongoing struggle to balance capital structure stability with the urgent need for R&D funding.

The persistent negative retained earnings suggest that the company has yet to establish a sustainable economic model, relying on equity issuance to offset operational deficits. This history of value erosion implies that future equity raises may continue to be dilutive to existing shareholders until the Axiomer platform demonstrates clear commercial viability.